Theralase(R) Investor Conference Call Reminder
Theralase (OTCQB: TLTFF) will host a conference call on Nov 19, 2025 at 11:00 am ET to review interim Phase II Study II data for BCG-unresponsive NMIBC CIS and 3Q2025 financial results.
As of Nov 7, 2025, 88 of 90 patients treated (97.8% enrollment); 72 completed required visits. Interim efficacy: 64.3% CR (54/84) and 72.6% TR (61/84); at 450 days 40% CR durability (18/45). Company expects enrollment complete in 4Q2025 with data lock and regulatory submissions in 1Q2027.
Financials: nine-month revenue $590,573 (-5% YoY), net loss $3,435,145 (+3% YoY); company raised $672,627 via private placement and has $280,000 short-term loans at 15% interest.
Theralase (OTCQB: TLTFF) ospiterà una conference call il 19 listopada 2025 alle 11:00 ET per rivedere i dati provvisori dello Studio II di Fase II per NMIBC CIS non rispondente al BCG e i risultati finanziari del 3Q2025.
Al 7 novembre 2025, 88 di 90 pazienti trattati (97,8% di enrollment); 72 hanno completato le visite richieste. Efficacia provvisoria: 64,3% CR (54/84) e 72,6% TR (61/84); a 450 giorni 40% durabilità CR (18/45). L'azienda prevede che l'enrollment sia completo nel 4Q2025 con data lock e presentazioni regolamentari nel 1Q2027.
Finanza: ricavi a nove mesi $590.573 (-5% YoY), perdita netta $3.435.145 (+3% YoY); l'azienda ha raccolto $672.627 tramite private placement e ha $280.000 di prestiti a breve termine al 15% di interesse.
Theralase (OTCQB: TLTFF) celebrará una conferencia telefónica el 19 de noviembre de 2025 a las 11:00 a. m. ET para revisar datos interinos del Estudio II de Fase II para NMIBC CIS no sensible al BCG y los resultados financieros del 3T2025.
Al 7 de novienbre 2025, 88 de 90 pacientes tratados (97,8% de inscripción); 72 completaron las visitas requeridas. Eficacia interina: 64,3% CR (54/84) y 72,6% TR (61/84); a 450 días 40% durabilidad CR (18/45). La empresa espera completar la inscripción en 4Q2025 con bloqueo de datos y presentaciones regulatorias en 1Q2027.
Finanzas: ingresos de nueve meses $590,573 (-5% interanual), pérdida neta $3,435,145 (+3% interanual); la empresa recaudó $672,627 mediante colocación privada y tiene $280,000 de préstamos a corto plazo al 15% de interés.
Theralase (OTCQB: TLTFF)는 2025년 11월 19일 오전 11:00 ET에 컨퍼런스 콜을 개최하여 BCG에 반응하지 않는 NMIBC CIS에 대한 2상 II상 중간 데이터를 검토하고 3Q2025 재무실적을 발표합니다.
2025년 11월 7일 기준, 90명 중 88명의 치료를 완료했고(등록률 97.8%), 72명이 필요한 방문을 완료했습니다. 중간 효능: CR 64.3% (54/84) 및 TR 72.6% (61/84); 450일 시점 CR 지속성 40% (18/45). 회사는 4Q2025에 등록 완료를 예상하고 데이터 잠금 및 규제 제출을 1Q2027에 수행할 예정입니다.
재무: 9개월 매출 $590,573 (-전년동기 대비 -5%), 순손실 $3,435,145 (+전년동기 대비 +3%); 회사는 사모 배치를 통해 $672,627를 조달했고 단기 대출 $280,000를 15% 이자율로 보유하고 있습니다.
Theralase (OTCQB: TLTFF) organisera une conférence téléphonique le 19 novembre 2025 à 11 h 00 HE pour examiner les données intermédiaires de l’étude de phase II sur le NMIBC CIS non réactif au BCG et les résultats financiers du 3T2025.
Au 7 novembre 2025, 88 sur 90 patients traités (taux d’inscription de 97,8 %); 72 ont effectué les visites requises. Efficacité intermédiaire : CR 64,3 % (54/84) et TR 72,6 % (61/84); à 450 jours, durabilité de CR de 40 % (18/45). La société prévoit que l’inscription sera complète au 4Q2025 avec verrouillage des données et soumissions réglementaires au 1Q2027.
Finances : revenus sur neuf mois $590 573 (-5 % YoY), perte nette $3 435 145 (+3 % YoY); la société a levé $672 627 via une placement privé et détient des prêts à court terme de $280 000 à un taux d’intérêt de 15 %.
Theralase (OTCQB: TLTFF) wird am 19. November 2025 um 11:00 Uhr ET einen Konferenzanruf abhalten, um Interimsdaten der Phase-II-Studie II für BCG-unempfindliches NMIBC CIS zu überprüfen und die Finanzergebnisse des 3Q2025 zu erläutern.
Stand vom 7. November 2025 sind 88 von 90 Patienten behandelt worden (98% Einschreibung); 72 haben erforderliche Besuche abgeschlossen. Zwischenbilanz Wirksamkeit: 64,3% CR (54/84) und 72,6% TR (61/84); nach 450 Tagen 40% CR-Dauerhaftigkeit (18/45). Das Unternehmen erwartet, die Einschreibung im 4Q2025 abzuschließen, mit Datenfreigabe und regulatorischen Einreichungen im 1Q2027.
Finanzen: Umsatz der ersten neun Monate $590,573 (-5% YoY), Nettoverschuldung $3,435,145 (+3% YoY); das Unternehmen hat $672,627 durch Privatplatzierung aufgenommen und besitzt $280,000 Kurzzeitdarlehen zu 15% Zinsen.
Theralase (OTCQB: TLTFF) ستعقد مكالمة مؤتمر عبر الهاتف في 19 نوفمبر 2025 الساعة 11:00 قديم بالتوقيت الشرقي لمراجعة بيانات المرحلة II المتوسطة للدراسة II لـ NMIBC CIS غير المستجيب لـ BCG والتقارير المالية للربع الثالث من 2025.
حتى 7 نوفمبر 2025، تم علاج 88 من 90 مريضاً (إشغال 97.8%); أكمل 72 زيارة مطلوبة. الفاعلية المؤقتة: CR 64.3% (54/84) و TR 72.6% (61/84); على مدى 450 يوماً، مدة CR 40% (18/45). تتوقع الشركة إكمال التسجيل في الربع الرابع من 2025 مع إغلاق البيانات وتقديمات تنظيمية في الربع الأول من 2027.
المالية: إيرادات تسعة أشهر $590,573 (-5% سنوياً)، الخسارة الصافية $3,435,145 (+3% سنوياً); رفعت الشركة $672,627 من خلال طرح خاص وتملك $280,000 قروض قصيرة الأجل بفائدة 15%.
- Complete Response rate 64.3% (54/84)
- Total Response rate 72.6% (61/84)
- 88/90 patients treated (97.8% enrollment)
- Enrollment on track to complete in 4Q2025
- Raised $672,627 via non-brokered private placement
- Revenue declined 5% to $590,573 (nine months)
- Net loss increased 3% to $3,435,145 (nine months)
- Administrative expenses rose 12% to $1,444,687
- $280,000 short-term loans outstanding at 15% interest
Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company's ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") ("Study II"), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025.
Participants are encouraged to submit questions in advance to mperraton@theralase.com to ensure sufficient time for discussion.
Zoom Meeting Link: https://us02web.zoom.us/j/81044841120
Webinar ID: 810 4484 1120
Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom
An archived version will be available on the website following the conference call.
Study II Update:
As of November 7, 2025:
- 88 patients have been treated with the primary Study Procedure, representing
97.8% of the targeted enrollment of 90 patients - 72 patients have completed the clinical study, having been assessed at all required visits or removed by the principal investigator for lack of response
- 16 patients remain pending study completion
Interim Clinical Results Demonstrate:
64.3% (54/84) of patients achieved a Complete Response ("CR") at any point in time.72.6% (61/84) achieved a Total Response (TR = CR + Indeterminate Response ("IR")).- At the 450-day assessment,
40% (18/45) of patients maintained a CR42.2% (19/45) maintained a TR, demonstrating durability of response.
Theralase® remains on track to complete enrollment in 4Q2025, with data lock and regulatory submissions expected in 1Q2027.
Financial Update:
Theralase® has released its unaudited, condensed, consolidated, interim 3Q2025 financial statements for the period ended September 30, 2025.
Financial Highlights - Nine Months Ended September 30, 2025 versus 2024:
- Revenue decreased
5% to$590,573 from$622,984. - Cost of sales decreased
10% to$299,743 (51% of revenue). - Gross margin remained stable at
$290,830 (49% of revenue). - Selling expenses decreased
18% to$212,421 . - Administrative expenses increased
12% to$1,444,687 . - Research and development expenses increased
1% to$2,116,540 , reflecting increased activity to support Study II progress. - Net loss increased
3% to$3,435,145 , including$708,521 in non-cash expenses such as amortization and stock-based compensation.
Operational Highlights:
$672,627 raised via non-brokered private placement (July 28, 2025)- Warrant extensions completed August 29, 2025
$280,000 in outstanding short-term loans as of November 7, 2025 at15% interest- The Company continues to evaluate equity and non-dilutive funding opportunities to support clinical and commercial milestones
For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at www.sedarplus.ca.
About Ruvidar®:
Ruvidar® (TLD-1433) is a small molecule, able to be activated by light, radiation, sound and other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of cancer, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274715
FAQ
When is Theralase (TLTFF) hosting the investor conference call?
What interim Phase II results did Theralase (TLTFF) report on Nov 17, 2025?
How close is Theralase (TLTFF) to completing enrollment for Study II?
What durability did Theralase (TLTFF) report at the 450-day assessment?
What were Theralase's (TLTFF) key nine-month financials through Sept 30, 2025?
What financing and liabilities did Theralase (TLTFF) disclose on Nov 17, 2025?
